Abstract. Bee venom phospholipase A2 (bvPLA2) is a prototypic group III enzyme which consists of unique N-terminal and C-terminal domains and a central secretory PLA2 (sPLA2) domain. This sPLA2 domain is highly homologous with human group III sPLA2. Current evidence suggests that group III sPLA2 may affect some neuronal functions, such as neuritogenesis, neurotransmitter release and neuronal survival. The prion diseases are neurodegenerative disorders characterized by the conversion of the normal cellular prion (PrPC) to the misfolded isoform scrapie prion protein (PrPSc). PrPSc accumulation in the central nervous system (CNS) leads to neurotoxicity by inhibition of the PI3K/AKT pathway or activation of p38 mitogen-activated protein kinase (MAPK) pathways. In the present study, we found that bvPLA2 inhibited prion protein (PrP) fragment (106-126)-induced neuronal cell death. PrP(106-126)-mediated increase of p-p38 MAPK and cleaved caspases and decrease of p-AKT were blocked by bvPLA2 treatment. These results indicate that increasing PLA2, including the group III sPLA2 is key to regulating PrP(106-126)-mediated neurotoxicity. Taken together, the results of this study suggest that specific modulation of PLA2 appears to prevent neuronal cell death caused by prion peptides.
Introduction
Transmissible spongiform encephalopathies, also known as prion diseases, are a family of progressive neurodegenerative disorders characterized by central nervous system (CNS) spongiosis, neuronal loss, and accumulation of scrapie prion protein (PrPSc) in the brain (1) . One of the main characteristics of prion disease pathogenesis is the formation of PrPSc, a proteinase K-resistant prion protein (PrP) which is a misfolded form of normal cellular prion protein (PrPC) (2) . PrPSc is derived from PrPC as a result of conformational conversion (1, 3, 4) . The presence of PrPC, thus, is required for PrPSc accumulation within the CNS and the progression of prion diseases (5, 6) . The membrane-linked form of PrPC, which is anchored to the cell surface via a glycosyl-phosphatidylinositol (GPI) -linkage, is expressed in neuronal cells (7, 8) . PrPC has various physical properties, including protection from oxidative stress, transmembrane signaling, control of copper homeostasis, and cell adhesion (9, 10) .
Although the mechanisms of PrPSc neurotoxicity are yet unclear, recent studies support the hypothesis that PrPSc induces neuronal cell death and activates caspase-3 through the p38-JNK mitogen-activated protein kinase (MAPK) pathway (2, 11, 12) . Seo et al studying PrP peptide 106-126 [PrP(106-126)]-treated SH-SY5Y cells, have shown that PrP(106-126)-induced neurotoxicity is decreased by repression of p38 MAPK activation with exposure to the SIRT1 activator, resveratrol (13) .
PrP(106-126) contains the amino acid residues 106-126 of PrPC and possesses many characteristics of the entire PrPSc including the capacity to cause neurotoxicity in hippocampal neuronal cells which catalyze the aggregation of endogenous PrPC to fibril accumulation (14, 15) . These properties are useful for the in vitro study of PrPSc pathogenesis (16) .
Phospholipase A2 (PLA2) is a lipolytic enzyme that catalyzes the hydrolysis of the sn-2 ester linkage of glycerophospholipids to liberate free fatty acids and lysophospholipids (17) . Cellular functions of PLA2s are known to modulate the release of arachidonic acid and the generation of eicosanoids, which are potent inflammatory mediators (18) . Furthermore, PLA2 plays a central role in host defense, differentiation (19) , and membrane remodeling (20) . PLA2 enzymes are found in a variety of sources including the mammalian pancreas, synovial fluids, and the venom of organisms including reptiles, insects, amphibians, arachnids, and coelenterates (21) . The PLA2 superfamily is subdivided into 15 groups on the basis of the homology of their structure, source, and localization (22) . Distribution among these groups can be classified into secretory PLA2 (sPLA2, groups I, II, III, V, IX, X, XI, XII, XIII and XIV), Ca 2+ -dependent cytosolic PLA2 (cPLA2, group IV), and Ca 2+ -independent cytosolic PLA2 (iPLA2, group VI) (20) .
The sPLA2 family represents a group of structurally homologous, Ca 2+ -dependent, low-molecular weight enzymes. Individual sPLA2s exhibit specific tissue and cellular localizations. As such, it is proposed that they perform distinct biological roles by activating different target substrates (23) . Group IA sPLA2 is involved in digestion, while, group II sPLA2 is involved in antibacterial defense (22) . Additionally, the function of group III sPLA2 is as a regulator of inflammation, proliferation, fertility, and maturation in mammals (19, 24, 25) .
Group III sPLA2 is a typical sPLA2 member, homologous with bee venom phospholipase A2 (bvPLA2) compared to other mammalian sPLA2s (26) . Recent studies suggested that Group III sPLA2 mediates atherosclerosis and differentiation of sperm maturation and fertility in transgenic mice (24, 25) . Additionally, this enzyme is known to regulate neuronal outgrowth and survival by activation of AKT (19) . One report suggested its use as a pharmacological therapy for Alzheimer's disease via enhanced α-secretase-dependent amyloid precursor protein (APP) processing by regulation of membrane fluidity (27) ; however, the effect of group III sPLA2 enzymes on PrP(106-126)-mediated neurotoxicity has not been reported.
Thus, the present study focused on the influence of bvPLA2 on the regulation of PrP(106-126)-induced apoptosis in neuronal cells. The results showed that neuronal cells exposed to bvPLA2 experienced decreased PrP(106-126)-mediated neurotoxicity. The present results suggest that regulation of group III PLA2 is a viable therapeutic strategy for neurodegenerative diseases including prion disease.
Materials and methods
Cell culture. Human neuroblastoma cell lines (SH-SY5Y) were obtained from the American Type Culture collection (ATCC, Rockville, MD, USA). Cells were cultured in Minimum Essential Medium (Hyclone Laboratories, Logan, UT, USA) that contained 10% fetal bovine serum (InvitrogenGibco, Grand Island, NY, USA) and gentamycin (0.1 mg/ml) in a humidified incubator maintained at 37˚C and 5% CO 2 .
PrP(106-126) treatment. Synthetic PrP(106-126) (sequence, Lys-Thr-Asn-Met-Lys-His-Met-Ala-Gly-Ala-Ala-Ala-Ala-GlyAla-Val-Val-Gly-Gly-Leu-Gly) peptides were synthesized from Peptron (Seoul, Korea). The peptides were dissolved in sterile DMSO at a concentration of 12.5 mM and stored at -80˚C.
Lactate dehydrogenase (LDH) assay. Cytotoxicity was assessed by the LDH assay in the supernatant medium using a LDH Cytotoxicity Detection kit (Takara Bio, Inc., Tokyo, Japan) according to the manufacturer's protocol. The LDH activity was determined by measuring the absorbance at 490 nm using a microplate reader (Spectra Max M2, Molecular Devices, USA).
Annexin V assay. Apoptosis was assessed by the Annexin V assay in the detached cells using an Αnnexin V assay kit (Santa Cruz Biotechnology) according to the manufacturer's protocol. Annexin V measurement was determined by measuring the fluorescence at excitation 488 nm and emission 525/30 using a Guava easyCyte HT (Millipore).
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. TUNEL analysis was performed to measure the degree of cellular apoptosis using an in situ ApoBrdU DNA fragmentation assay kit (BioVision, San Francisco, CA, USA) following the manufacturer's instructions. Cells were washed with phosphate buffer saline (PBS) and fixed with paraformaldehyde for 15 min. Cells were pre-incubated with 50 µl DNA-labelling solution (10 µl TdT reaction buffer, 0.75 µl TdT enzyme, 8 µl Br-dUTP) for 1 h at 37˚C and then cells were incubated with 5 µl anti-BrdU-FITC antibody for 0.5 h at room temperature (20˚C). Finally, cells were mounted with DakoCytomation fluorescent medium and visualized usiong fluorescence microscopy. Cells were counterstained with propodium iodide (PI) to show all cell nuclei.
Western blot analyses. SH-SY5Y was lysed in a lysis buffer (25 mM HEPES; pH 7.4, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl 2 , 0.1 mM DTT and protease inhibitor mixture). Proteins were electrophoretically resolved on a 10-15% sodium dodecyl sulfate (SDS) gel, and immunoblotting was performed as previously described. Equal amounts of lysate protein were resolved on a 10-15% SDS-polyacrylamide gel and electrophoretically transferred to a nitrocellulose membrane. Immunoreactivity was detected through sequential incubation with horseradish peroxidase-conjugated secondary antibodies and ECL reagents. The antibodies used for immunoblotting were caspase-3, p38, phospho-p38 (all from Cell Signaling Technology), AKT (Calbiochem), phospho-AKT (Calbiochem) and β-actin (Sigma). Images were examined using an Fusion-FX7 imaging system (Vilber Lourmat).
Results

PrP(106-126)-mediated neurotoxicity is attenuated by bvPLA2 treatment in SH-SY5Y neuroblastoma cells.
The influence of bvPLA2 on PrP(106-126)-mediated neurotoxicity in SH-SY5Y cells was determined by the Annexin V assay. SH-SY5Y cells were exposed to bvPLA2 with or without PrP(106-126). Treatment of SH-SY5Y cells with PrP(106-126), but not bvPLA2, resulted in neurotoxicity, identified by the fact that Annexin V positive cells were 59.51% increased after 24 h (Fig. 1A and B) . However, treatment with bvPLA2 inhibited PrP(106-126)-mediated neurotoxicity in SH-SY5Y cells (Fig. 1) . These results were confirmed by examination of LDH-releasing levels (Fig. 1D) . Consistent with these results, the TUNEL assay and immunoblotting of activated caspase-3 also showed that bvPLA2 treatment completely inhibited PrP(106-126)-induced apoptosis (Figs. 1C and 2 ). These result suggest that bvPLA2 attenuates PrP(106-126)-induced apoptosis in neuronal cells.
Administration of bvPLA2 inhibits PrP(106-126)-induced neuronal cell death by regulating the activation of AKT and p38 MAPK proteins.
Because group III sPLA2 can regulate both neuronal survival and neurite outgrowth via regulation of AKT (19), we investigated whether bvPLA2 had an effect on AKT, p38 MAPK and caspase-3 protein levels. SH-SY5Y cells were pre-incubated with different concentrations of bvPLA2 for 1 h then exposed to PrP(106-126) (Fig. 2) . The PrP(106-126)-treated cells showed increased phosphorylated-p38 protein levels and decreased phosphorylated-AKT protein levels. By contrast, bvPLA2 administration was associated with decreased p-p38 protein levels and increased p-AKT protein levels in SH-SY5Y cells treated with PrP(106-126) (Fig. 2) , in a dose dependent manner. The results indicate that treatment with bvPLA2 prevents prion peptide-induced apoptosis by regulating AKT and p38 MAPK activation.
To determine whether bvPLA2 operates by activating AKT and p38 MAPK proteins to inhibit PrP(106-126)-induced apoptosis, SH-SY5Y cells were pre-treated with bvPLA2, AKT inhibitor, wortmannin, and p38 inhibitor, SB-203580, and then exposed to PrP(106-126) (Figs. 3 and 4) . First, we evaluated the influence of AKT activation on the protective effect of bvPLA2 on cells after exposure to PrP(106-126). Administration of bvPLA2 decreased Annexin V positive cells following treatment with PrP(106-126), but this effect was blocked by treatment with the AKT inhibitor wortmannin (Fig. 3A and B) . These results were confirmed by examination of LDH-releasing levels (Fig. 3D) . Consistent with these findings, the TUNEL assay and Western blot analysis also showed that pre-treatment with wortmannin blocked the protective effect of bvPLA2 on PrP(106-126) neurotoxicity and decreased the activation of AKT (Fig. 3C and E) . Next, to determine whether bvPLA2 had a neuroprotective effect associated with Figure 2 . Effects of bee venom PLA2 (bvPLA2) treatment on AKT and p38 phosphorylations on PrP(106-126)-mediated neuronal cell death. SH-SY5Y cells were pretreated with bvPLA2 (1 h) in a dose-dependent manner, and then exposed to 50 µM PrP(106-126) for 15 h. The treated cells were assessed for AKT, p-AKT, p38, p-p38 and caspase-3 and cleaved caspase-3 production by Western blot analysis. (Fig. 4A and B) . These results were confirmed by examination of LDH-releasing levels (Fig. 4D) . Consistent with these results, the TUNEL assay and Western blot analysis also showed that pre-treatment with bvPLA2 or SB-203580 blocked the neurotoxicity associated with PrP(106-126) and decreased the activation of p38 MAPK ( Fig. 4C and E) .
Collectively, these results support the hypothesis that bvPLA2 acts by increasing p-AKT protein levels and decreasing p-p38 protein levels to reduce PrP(106-126)-mediated neurotoxicity.
Discussion
The purpose of this study was to explore a potential mechanism responsible for group III sPLA2-mediated protective effects against prion disease. The results support the efficacy of group III sPLA2, including bvPLA2 from Apis mellifica, for use in therapeutic strategies against prion-mediated neurodegeneration.
Prion diseases are a family of neurodegenerative disease characterized by neuronal vacuolation, gliosis, and astrocytosis triggered by conversion of PrPC to the scrapie-associated misfolded PrP isoform, PrPSc (1). PrP(106-126) possess physicochemical properties similar to PrPSc, including neurotoxicity and β-sheet formation (28) (29) (30) (31) . Some reports showed that PrP(106-126)-mediated neurotoxicity is related to endoplasmic reticulum stress and mitochondrial disruption, and thereby to induction of AKT and p38 MAPK-dependent apoptosis (29, 32, 33) . In this study, PrP(106-126) induced apoptosis, inactivated PI3K/AKT pathways, and activated the p38 MAPK and caspase-3 pathways (Figs. 1 and 2) . Interestingly, these neurotoxic pathways were inhibited by bvPLA2 treatment, resulting in a neuroprotective effect against PrP(106-126)-mediated neuronal cell death (Figs. 1 and 2) .
Some reports have shown that the activity of PLA2 influences the progression of neurodegenerative diseases including prion disease (34) . Findings from the studies by Bate et al showed that inhibition of PLA2 inhibited prion-mediated neuronal cell death (35) ; however, this effect can differ depending on the PLA2 member (20) . Several reports investigated how cPLA2 influences prion-mediated neurotoxicity while sPLA2 does not (34) . Also, a recent study suggested that group III PLA2 prevents Alzheimer's disease in a transgenic mouse model (27) . Consistent with this, bvPLA2-treated SH-SY5Y cells were protected against PrP(106-126)-mediated neuronal cell death.
Group III sPLA2, is a subfamily of secreted PLA2. A recent study suggested a therapeutic strategy to regulate Alzheimer's disease by enhancing α-secretase-dependent APP processing (19, 27) . As a member of group III sPLA2, bvPLA2 possesses structural and biochemical properties homologous to human group III PLA2, including the ability to regulate neurite outgrowth and mediate atherosclerosis (26, 36) . A recent study showed that group III sPLA2, including bvPLA2, acts through modulation of PI3K/AKT signaling in neuritogenesis (19) . Consistent with these results, PrP(106-126)-induced AKT inactivation was regulated by bvPLA2 treatment in SH-SY5Y neuronal cells (Fig. 3E) . These results indicate that bvPLA2-mediated regulation of PI3K/AKT signaling may be a crucial target for the blockade of PrP(106-126)-mediated neurotoxicity.
Some reports have shown that bee venom attenuates neuroinflammatory events by regulation of p38 MAPK signaling in neurodegenerative diseases (36, 37) . However, the effect of bvPLA2 enzymes on p38 MAPK activity in neurodegenerative disorders has not been reported. In the present study, we showed that bvPLA2 prevents PrP(106-126)-mediated neuronal cell death by inactivation of p38 MAPK (Fig. 4) .
It remains questionable whether gene regulation of human group III sPLA2 would produce similar effects to that by bvPLA2 administration to PrP(106-126)-treated cells. Further study is required to illustrate the influence of human group III sPLA2 on PrP(106-126)-mediated neurotoxicity in vitro and/or in vivo. Collectively, the results suggest that bvPLA2 prevents neurotoxicity induced by PrP(106-126) through regulation of p38 MAPK and AKT activation. This is the first study to identify the neuro protective effects of group III sPLA2 against PrP(106-126)-mediated neurotoxicity and also, suggests that prion-related neurodegenerative diseases may be attenuated by using group III sPLA2 activators, including bvPLA2.
